This trial is evaluating whether Aurora A Kinase Inhibitor LY3295668 will improve 1 primary outcome and 3 secondary outcomes in patients with Advanced Lung Non-Squamous Non-Small Cell Carcinoma. Measurement will happen over the course of Date of treatment started until the criteria for disease progression is met, assessed at 6 months after treatment.
This trial requires 30 total participants across 1 different treatment group
This trial involves a single treatment. Aurora A Kinase Inhibitor LY3295668 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
"For men in the early 20s who had never smoked, there was a 26% chance of developing NSCLC within 10 years of diagnosis. The risk increased with smoking status; 34% of current smokers developed NSCLC compared with 18% of ex-smokers." - Anonymous Online Contributor
"The overall 5-year survival rate was 17.5%, which was lower than the national average. Survival rates were better in the earlier years after diagnosis, but declined later. Patients diagnosed in more recent years had poorer survival compared to older patients." - Anonymous Online Contributor
"The similarity between spontaneous and familial nonsmoking carcinomas suggests that their genetic susceptibility depends on environmental factors in addition to hereditary ones. This indicates that age at diagnosis is a better predictor of prognosis than family history of lung cancer." - Anonymous Online Contributor
"Results from a recent clinical trial suggest that Aurora A inhibitors such as Ly3295668 may serve as novel anti-cancer agents and as a novel class of therapeutics for treating cancers associated with the deregulation of the Aurora A pathway." - Anonymous Online Contributor
"The survival rate for patients with carcinoma, non-small-cell lung without metastases was poorer than that for those with distant metastases. In addition, the risk factors of death were different between patients with carcinoma, non-small-cell lung without metastases and those with distant metastases." - Anonymous Online Contributor
"Small cell carcinoma of the lung has a dismal prognosis. Survival rates based on stage of disease (TNM classification) were analyzed. The survival rate of T1a small cell carcinoma was 11%. The survival rates of T1b and T2 tumors were 14% and 31%, respectively; and those of T3 and T4 tumors were 21% and 16%, respectively. In addition to TNM staging system, other factors such as the presence of visceral metastasis and the presence of brain metastasis should also be considered. The overall 5-year survival rate for small cell carcinoma of the lung is 19%. We believe that this information may help physicians to counsel patients regarding their prognosis and to provide appropriate expectations." - Anonymous Online Contributor
"In a recent study, we observed that the most common side effects were fatigue, rash, dizziness, nausea, headache, and insomnia. These side effects were mild to moderate in severity and generally reversible upon discontinuation of therapy. No unexpected side effects were reported. The present data provide valuable information regarding the expected pharmacokinetics and safety profile of aurora A kinase inhibitors." - Anonymous Online Contributor
"The authors' findings support the role of clinical trials for NSCLC; however, they emphasize an important limitation of the study: the lack of a control arm in the propensity score analyses. They conclude that there are no specific criteria to determine who should be offered clinical trials for NSCLC." - Anonymous Online Contributor
"Findings from a recent study of clinical trial NCT02088982 seem to suggest that Aurora A kinase inhibition might be more effective than standard chemotherapy in NSCLC patients and it needs further evaluation in combination with platinum chemotherapy." - Anonymous Online Contributor
"Aurora A kinase inhibition was shown to have significant antitumor activity in both xenografts and primary tumors from NSCLC patients, supporting further development of Aurora A inhibitors as novel therapeutics against this disease." - Anonymous Online Contributor
"In this review, researchers consider the effectiveness of different therapies and the most effective agents to treat carcinomas, non-small-cell lung. Data from a recent study show that the combination therapy has better efficacy than single agent therapy or monotherapy. Moreover, the curative effect is dependent on the type of tumor, the stage, and the degree of metastasis. Additionally, the combination therapy has better efficacy than monotherapy and the two-drug combination therapy has better efficacy than a single agent regimen. There are many types of therapy, and the best therapy depends on the probability of survival in each case. Finally, we summarize the most recent research of carcinoma, non-small-cell lung." - Anonymous Online Contributor